scholarly journals Associations of Omega-3 fatty acids with brain morphology and volume in cognitively healthy older adults: A narrative review

2021 ◽  
Vol 67 ◽  
pp. 101300
Author(s):  
Tony Macaron ◽  
Kelly Virecoulon Giudici ◽  
Gene L. Bowman ◽  
Alan Sinclair ◽  
Elie Stephan ◽  
...  
2020 ◽  
Vol 37 (2) ◽  
pp. 656-670 ◽  
Author(s):  
Daniel E. Hilleman ◽  
Barbara S. Wiggins ◽  
Michael B. Bottorff

2019 ◽  
Vol 75 (5) ◽  
pp. 875-884 ◽  
Author(s):  
Souzana-Eirini Xyda ◽  
Ivan Vuckovic ◽  
Xuan-Mai Petterson ◽  
Surendra Dasari ◽  
Antigoni Z Lalia ◽  
...  

Abstract Omega-3 polyunsaturated fatty acids (n3-PUFA) are well recognized for their potent triglyceride-lowering effects, but the potential influence of these bioactive lipids on other biological processes, particularly in the context of healthy aging, remains unknown. With the goal of gaining new insight into some less well-characterized biological effects of n3-PUFAs in healthy older adults, we performed metabolomics of fasting peripheral blood plasma collected from 12 young adults and 12 older adults before and after an open-label intervention of n3-PUFA (3.9 g/day, 2.7 g eicosapentaenoic [EPA], 1.2 g docosahexaenoic [DHA]). Proton nuclear magnetic resonance (1H-NMR) based lipoprotein subclass analysis revealed the expected reduction in total triglyceride (TG), but also demonstrated that n3-PUFA supplementation reduced very low-density lipoprotein (VLDL) particle number, modestly increased high-density lipoprotein (HDL) cholesterol, and shifted the composition of HDL subclasses. Further metabolite profiling by 1H-NMR and mass spectrometry revealed pronounced changes in phospholipids, cholesterol esters, diglycerides, and triglycerides following n3-PUFA supplementation. Furthermore, significant changes in hydroxyproline, kynurenine, and 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF) following n3-PUFA supplementation provide further insight into some less well-recognized biological effects of n3-PUFA supplementation, including possible effects on protein metabolism, the kynurenine pathway, and glucose metabolism.


2011 ◽  
Vol 94 (2) ◽  
pp. 527-533 ◽  
Author(s):  
Luc Djoussé ◽  
Mary L Biggs ◽  
Rozenn N Lemaitre ◽  
Irena B King ◽  
Xiaoling Song ◽  
...  

2013 ◽  
Vol 27 (S1) ◽  
Author(s):  
Gene Bowman ◽  
HIroko Dodge ◽  
Jeffrey Kaye ◽  
Joseph Quinn

2017 ◽  
Vol 31 (7) ◽  
pp. 724-734 ◽  
Author(s):  
Nadia D. Andruchow ◽  
Kyoko Konishi ◽  
Bryna Shatenstein ◽  
Véronique D. Bohbot

Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 6094
Author(s):  
Karlen Stade Bader-Larsen ◽  
Elisabeth Anne Larson ◽  
Maria Dalamaga ◽  
Faidon Magkos

Interest in dietary supplements and their efficacy in treating and preventing disease has increased greatly since the outbreak of the COVID-19 pandemic. Due to the risk of severe COVID-19 in patients with cancer, we conducted a narrative review aiming to better understand the data on the safety of the most efficacious “anti-COVID-19” nutraceuticals for patients with cancer. We conducted a PubMed database search aimed at identifying the most effective nutrients for use against COVID-19. For the identified nutraceuticals, we searched PubMed again regarding their safety for patients with cancer. Fifty-four total records (52 independent studies) were retrieved, pertaining to vitamin D, vitamin C, selenium, omega-3 fatty acids, and zinc. Vitamin D results from 23 articles indicated safe use, but two articles indicated potential harm. All 14 articles for vitamin C and five out of six articles for selenium indicated the safety of use (one study for selenium suggested harm with high-dose supplementation). Results for omega-3 fatty acids (seven articles) and zinc (one article), however, were rather mixed regarding safety. We conclude that vitamin D, vitamin C, and selenium supplements are likely safe or even beneficial at typically recommended doses; however, caution is urged with omega-3 fatty acid supplements, and zinc supplements should likely be avoided. More experimental research is needed, and nutraceutical use by patients with cancer should always be under the supervision of a healthcare team.


Sign in / Sign up

Export Citation Format

Share Document